Zahari Raykov

747 total citations
21 papers, 650 citations indexed

About

Zahari Raykov is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Zahari Raykov has authored 21 papers receiving a total of 650 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Genetics, 9 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Zahari Raykov's work include Virus-based gene therapy research (17 papers), RNA Interference and Gene Delivery (6 papers) and Animal Virus Infections Studies (6 papers). Zahari Raykov is often cited by papers focused on Virus-based gene therapy research (17 papers), RNA Interference and Gene Delivery (6 papers) and Animal Virus Infections Studies (6 papers). Zahari Raykov collaborates with scholars based in Germany, France and Bulgaria. Zahari Raykov's co-authors include Jean Rommelaere, Marc Aprahamian, Assia L. Angelova, Svitlana P. Grekova, Ginette Balboni, Laurent Daeffler, Nathalia A. Giese, Barbara Leuchs, Christiane Dinsart and Irina Kiprianova and has published in prestigious journals such as PLoS ONE, Journal of Virology and Clinical Cancer Research.

In The Last Decade

Zahari Raykov

21 papers receiving 641 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zahari Raykov Germany 13 544 358 234 218 115 21 650
Assia L. Angelova Germany 14 582 1.1× 440 1.2× 250 1.1× 224 1.0× 104 0.9× 34 733
Candice Willmon United States 11 566 1.0× 409 1.1× 272 1.2× 108 0.5× 133 1.2× 17 683
Svitlana P. Grekova Germany 10 313 0.6× 236 0.7× 136 0.6× 134 0.6× 62 0.5× 14 438
Shyambabu Chaurasiya United States 18 414 0.8× 406 1.1× 203 0.9× 86 0.4× 124 1.1× 33 636
Christian Grossardt Germany 9 531 1.0× 360 1.0× 203 0.9× 108 0.5× 95 0.8× 10 645
Mari Hirvinen Finland 13 651 1.2× 550 1.5× 361 1.5× 113 0.5× 196 1.7× 19 878
Margaret R. Duffy United Kingdom 14 500 0.9× 445 1.2× 386 1.6× 90 0.4× 83 0.7× 25 705
Mohan Kuppuswamy United States 13 816 1.5× 388 1.1× 677 2.9× 179 0.8× 135 1.2× 20 977
Timo Joensuu Finland 18 716 1.3× 668 1.9× 367 1.6× 118 0.5× 176 1.5× 27 893
Naomi De Silva Canada 8 431 0.8× 357 1.0× 198 0.8× 70 0.3× 110 1.0× 10 520

Countries citing papers authored by Zahari Raykov

Since Specialization
Citations

This map shows the geographic impact of Zahari Raykov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zahari Raykov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zahari Raykov more than expected).

Fields of papers citing papers by Zahari Raykov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zahari Raykov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zahari Raykov. The network helps show where Zahari Raykov may publish in the future.

Co-authorship network of co-authors of Zahari Raykov

This figure shows the co-authorship network connecting the top 25 collaborators of Zahari Raykov. A scholar is included among the top collaborators of Zahari Raykov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zahari Raykov. Zahari Raykov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Angelova, Assia L., Svitlana P. Grekova, Anette Heller, et al.. (2014). Complementary Induction of Immunogenic Cell Death by Oncolytic Parvovirus H-1PV and Gemcitabine in Pancreatic Cancer. Journal of Virology. 88(10). 5263–5276. 64 indexed citations
2.
3.
Li, Junwei, Serena Bonifati, Séverine Valmary‐Degano, et al.. (2013). Synergistic combination of valproic acid and oncolytic parvovirus H‐1 PV as a potential therapy against cervical and pancreatic carcinomas. EMBO Molecular Medicine. 5(10). 1537–1555. 59 indexed citations
4.
Raykov, Zahari, Svitlana P. Grekova, Barbara Leuchs, et al.. (2013). TLR-9 Contributes to the Antiviral Innate Immune Sensing of Rodent Parvoviruses MVMp and H-1PV by Normal Human Immune Cells. PLoS ONE. 8(1). e55086–e55086. 16 indexed citations
5.
Grekova, Svitlana P., Jean Rommelaere, & Zahari Raykov. (2012). Parvoviruses-tools to fine-tune anticancer immune responses. OncoImmunology. 1(8). 1417–1419. 8 indexed citations
6.
Raykov, Zahari, et al.. (2012). Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection. Cancer Gene Therapy. 19(7). 468–475. 37 indexed citations
7.
Grekova, Svitlana P., Marc Aprahamian, Laurent Daeffler, et al.. (2011). Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer. Cancer Biology & Therapy. 12(10). 888–895. 32 indexed citations
8.
Grekova, Svitlana P., Assia L. Angelova, Laurent Daeffler, & Zahari Raykov. (2011). Pancreatic Cancer Cell Lines Can Induce Prostaglandin E2 Production from Human Blood Mononuclear Cells. Journal of Oncology. 2011. 1–5. 4 indexed citations
9.
Rommelaere, Jean, Karsten Geletneky, Assia L. Angelova, et al.. (2010). Oncolytic parvoviruses as cancer therapeutics. Cytokine & Growth Factor Reviews. 21(2-3). 185–195. 96 indexed citations
10.
Grekova, Svitlana P., Marc Aprahamian, Nathalia A. Giese, et al.. (2010). Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent. Cancer Biology & Therapy. 10(12). 1280–1289. 39 indexed citations
11.
Angelova, Assia L., Marc Aprahamian, Svitlana P. Grekova, et al.. (2009). Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1PV. Clinical Cancer Research. 15(2). 511–519. 81 indexed citations
12.
Angelova, Assia L., Marc Aprahamian, Ginette Balboni, et al.. (2009). Oncolytic Rat Parvovirus H-1PV, a Candidate for the Treatment of Human Lymphoma: In Vitro and In Vivo Studies. Molecular Therapy. 17(7). 1164–1172. 43 indexed citations
13.
Raykov, Zahari, Pétia Georgieva, Assia L. Angelova, Angel S. Galabov, & Jean Rommelaere. (2009). Anticancer effects of an oncolytic parvovirus combined with non-conventional therapeutics on pancreatic carcinoma cell lines. Acta Virologica. 53(1). 57–60. 4 indexed citations
14.
Raykov, Zahari, et al.. (2008). Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity. International Journal of Cancer. 122(12). 2880–2884. 39 indexed citations
15.
Raykov, Zahari & Jean Rommelaere. (2008). Potential of tumour cells for delivering oncolytic viruses. Gene Therapy. 15(10). 704–710. 15 indexed citations
16.
Angelova, Assia L., Angel S. Galabov, Jean Rommelaere, & Zahari Raykov. (2007). Antitumour effects of combined radio- and parvovirotherapy in n-Ras-positive tumour cells. 60(8). 879–882. 1 indexed citations
17.
Raykov, Zahari, Larissa Savelyeva, Ginette Balboni, et al.. (2005). B1 Lymphocytes and Myeloid Dendritic Cells in Lymphoid Organs Are Preferential Extratumoral Sites of Parvovirus Minute Virus of Mice Prototype Strain Expression. Journal of Virology. 79(6). 3517–3524. 11 indexed citations
18.
Raykov, Zahari, Ginette Balboni, Marc Aprahamian, & Jean Rommelaere. (2004). Carrier cell‐mediated delivery of oncolytic parvoviruses for targeting metastases. International Journal of Cancer. 109(5). 742–749. 53 indexed citations
19.
Raykov, Zahari, et al.. (2004). Folic Acid Role in Mutagenesis, Carcinogenesis, Prevention and Treatment of Cancer. Biotechnology & Biotechnological Equipment. 18(3). 125–135. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Assia L. Angelova Breakdown of academic impact, for papers by Candice Willmon Breakdown of academic impact, for papers by Svitlana P. Grekova Breakdown of academic impact, for papers by Shyambabu Chaurasiya Breakdown of academic impact, for papers by Christian Grossardt Breakdown of academic impact, for papers by Mari Hirvinen Breakdown of academic impact, for papers by Margaret R. Duffy Breakdown of academic impact, for papers by Mohan Kuppuswamy Breakdown of academic impact, for papers by Timo Joensuu Breakdown of academic impact, for papers by Naomi De Silva
Rankless by CCL
2026